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The diarylquinoline TMC207 kills Mycobacterium tuberculosis by specifically inhibiting ATP synthase. We
show here that human mitochondrial ATP synthase (50% inhibitory concentration [IC50] of >200 M)
displayed more than 20,000-fold lower sensitivity for TMC207 compared to that of mycobacterial ATP synthase
(IC50 of 10 nM). Also, oxygen consumption in mouse liver and bovine heart mitochondria showed very low
sensitivity for TMC207. These results suggest that TMC207 may not elicit ATP synthesis-related toxicity in
mammalian cells. ATP synthase, although highly conserved between prokaryotes and eukaryotes, may still
qualify as an attractive antibiotic target.
A new series of compounds, the diarylquinolines, was re-
ported to be highly active against Mycobacterium tuberculosis
(3). TMC207, the lead compound of the diarylquinoline series,
displays MICs of 30 nM for M. tuberculosis and 15 nM for
Mycobacterium smegmatis. We recently demonstrated that
TMC207 targets ATP synthase, the enzyme responsible for
ATP production by oxidative phosphorylation (11). The inhi-
bition of ATP synthase by TMC207 was highly specific, with a
50% inhibitory concentration (IC50) for this enzyme corre-
sponding to the MIC for bacterial growth inhibition (11). This
compound, which efficiently kills replicating as well as dormant
mycobacteria (12, 18), is currently in clinical development in
phase IIb trials in patients with multidrug-resistant tuberculosis.
An important factor to consider for a new antibacterial drug
is the lack of a eukaryotic homologue of the target, as inhibi-
tion of a homologous enzyme could lead to toxicity and safety
concerns in humans. In the case of TMC207, the target enzyme
ATP synthase is essential for survival in higher organisms, as it
supplies cells with the bulk of their ATP via oxidative phos-
phorylation (20). ATP synthase is evolutionarily strongly con-
served among prokaryotes and eukaryotes. Universally, ATP
synthesis is coupled to the flow of protons from the intercristae
region in mitochondria and the periplasmic space in bacteria to
the mitochondrial matrix and the bacterial cytoplasm, respec-
tively. Subunit c of ATP synthase, forming a membrane-span-
ning oligomer, is essential for this proton transport (8).
TMC207 binds to subunit c of mycobacterial ATP synthase
(11). Several natural compounds, such as oligomycin and
venturicidin, are known to block ATP synthase action by in-
teraction with subunit c. However, these compounds are not
selective and inhibit ATP synthase not only in bacteria but also
in mitochondria (14, 15). This lack of selectivity prevents their
clinical usage due to toxicity issues and fatality concerns. Mi-
tochondrial toxicity is a major concern in the clinical develop-
ment of new drugs, as it may lead to disease conditions, such as
pancreatitis, peripheral neuropathy, and cardial or skeletal
myopathies (1, 21).
Hence, it is of key importance to investigate the selectivity of
TMC207 towards mycobacterial ATP synthase compared with
that towards mitochondrial ATP synthase.
Mycobacterium smegmatis mc2155 was cultured and inverted
membrane vesicles were prepared as described previously (2,
11). The human ovarian cancer cell line OVCAR3 was grown
in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum and 100 units/ml penicillin-streptomycin. Mito-
chondria and submitochondrial particles (SMPs) were isolated
and prepared according to methods outlined previously (6, 9,
22). ATP synthesis activity by human mitochondria and myco-
bacterial membrane vesicles was measured as described previ-
ously (6, 9, 11). Mouse liver mitochondria and mitoplasts were
isolated and prepared from M18 mice as described previously
(4, 15). The method of Smith (19) was used to isolate bovine
heart mitochondria. Mitochondria or mitoplast oxygen con-
sumption rates were monitored according to the methods from
references 5 and 16.
First, we monitored the effect of TMC207 on ATP synthesis
in isolated mitochondria from a human cancer cell line. No
effect of TMC207 on ATP production was observed at nano-
molar concentrations; extremely high concentrations of 200
M compound lead to approximately 35% inhibition (Fig. 1A).
N,N-dicyclohexyl-carbodiimide (DCCD; 5 M) and oligomy-
cin (1 M), two nonselective ATP synthase inhibitors, both
suppressed ATP synthesis by 90% (Fig. 1A). In contrast,
ATP synthase within inverted membrane vesicles of M. smeg-
matis was efficiently inhibited by nanomolar concentrations of
TMC207. Half-maximal inhibition was achieved with 10 nM
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TMC207; virtually complete inhibition was achieved in the
presence of 100 nM compound (Fig. 1B). From the IC50s
obtained for human (IC50,200 M) and mycobacterial (IC50,
0.01 M) ATP synthase, a high selectivity index of 20,000 for
TMC207 was calculated. TMC207 has a strongly hydrophobic
core structure (3) and may get trapped in the mitochondrial
outer membrane. For this reason, we also investigated the
effect of TMC207 on SMPs, mitochondria from which the
outer membrane was removed by sonication treatment. How-
ever, as observed for whole mitochondria, human SMPs
showed only very low sensitivity for TMC207, with an IC50 of
200 M (Fig. 1A). Thus, the lack of susceptibility of human
ATP synthase cannot be accounted for by a permeability bar-
rier function of the mitochondrial outer membrane.
We then determined the effect of TMC207 on oxygen con-
sumption by mitochondria freshly isolated from mouse liver
and bovine heart tissue. In isolated mitochondria, any inhibi-
tion of ATP synthase or the respiratory chain enzyme com-
plexes will cause decreased oxygen consumption. Here, for
both mouse liver and bovine heart mitochondria, no significant
effect on oxygen consumption was measured for TMC207,
even in the presence of high (175 M) concentrations (Fig. 2).
As a control, oligomycin efficiently inhibited oxygen consump-
tion by 80% in mouse liver and 50% in bovine heart mi-
tochondria. Furthermore, ATP synthase and respiratory func-
tion in mitoplasts, mouse liver mitochondria from which the
outer membrane was removed by mild osmotic shock, were not
significantly inhibited by TMC207 (Fig. 2).
Taken together, mitochondria from human cells, mouse
liver, and bovine heart show only very low sensitivity for
TMC207. The high selectivity index for TMC207 indicates that
the compound is very specific and unlikely to induce target-
based toxicity in mammalian cells. In drug development, com-
pounds with a selectivity index of 1,000 are regarded as
promising candidates for clinical development. TMC207 may
thus be the first highly selective ATP synthase inhibitor with
the potential to treat a bacterial infection. In a phase I clinical
study with healthy volunteers, short-term administration of
TMC207 in humans was found to be safe and well tolerated
without serious adverse effects (3). Our results provide the
basis for a rational explanation of the preliminary clinical
safety observed with this compound.
It has previously been shown that the point mutations A63P
and I66M in subunit c (Fig. 3) lead to acquired resistance in M.
tuberculosis (3, 17). Furthermore, in certain mycobacterial spe-
cies like M. xenopi, M. shimoidei, and M. novocastrense, the
naturally occurring genetic polymorphism of A63M results in
intrinsic resistance (10). Docking studies based on binding
energy minimization have suggested that E61, A63, and I66
FIG. 1. Effect of TMC207 on ATP synthesis by mitochondria from a human cell line. ATP synthesis in the presence of TMC207 was measured
for mitochondria (250 g/ml) and SMPs (150 g/ml) from a human cancer cell line (A) and compared to that for inverted membrane vesicles of
Mycobacterium smegmatis (B). Samples were incubated at 25°C for 1 h in the presence of an ADP-regenerating system, and produced ATP was
quantified spectrophotometrically by monitoring the oxidation of glucose-6-phosphate with NADP. As controls, DCCD (100 M for M.
smegmatis and 5 M for human mitochondria and SMPs) and oligomycin (1 M) were used.
FIG. 2. Effect of TMC207 on respiratory function in mitochondria
isolated from mouse and bovine tissue. Oxygen consumption coupled
to ATP synthesis in the presence of TMC207 was measured for mito-
chondria from mouse liver, mitoplasts from mouse liver, and mito-
chondria from bovine heart (each at a final protein concentration of 1
mg/ml). The oxygen concentration was measured using a Clark elec-
trode at 37°C in a medium with 20 mM Tris-HCl, pH 7.3, 85 mM KCl,
5 mM KH2PO4, 2.3 mM MgCl2, 25 mM creatine, and 25 mM phos-
phocreatine in the presence of an ADP-regenerating system and the
indicated concentrations of TMC207. The membrane was energized by
an addition of succinate, and complex I was inhibited by rotenone.
Inhibition of ATP synthase and respiratory chain enzymes was deter-
mined as a decrease in the state III oxygen consumption rate. As a
control, oligomycin (0.6 M) was used. Each graph shows mean values
of three independent experiments with standard deviations.
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contribute to a binding pocket for TMC207 in the membrane-
spanning region of subunit c (7). Amino acid changes or nat-
ural polymorphisms in this binding pocket may cause steric
hindrance and thus prevent efficient binding of the drug. In-
terestingly, ATP synthases from human, mouse, and bovine
mitochondria also display a methionine at position 63 of sub-
unit c, and this polymorphism on its own may account for the
lack of inhibition of ATP synthase in mitochondria from these
organisms. Although in humans three different isoforms of
subunit c are known (13), no tissue-specific sensitivity for
TMC207 can be expected, as these isoforms represent the
same mature protein and differ only in the mitochondrial im-
port sequence.
Targeting the bacterial energy metabolism, despite the fact
that the enzymes involved are conserved among prokaryotes
and eukaryotes, is a valid approach and may help to combat the
increased emergence of drug resistance. More generally, our
results illustrate that in drug discovery, a protein should not be
disregarded a priori as a potential drug target because of the
existence of a human homologue.
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FIG. 3. Multiple sequence alignment for subunit c of ATP synthase. Amino acid sequences of ATP synthase subunit c from mycobacteria and
eukaryotic species are compared. Species abbreviations: M.tub, M. tuberculosis (Swiss-Prot accession no. Q10598); M.sme, M. smegmatis (EMBL
accession no. AJ862722); M.xen, M. xenopi (GenBank accession no. DQ306893); H.sap, Homo sapiens (residue 60 to 136; RefSeq accession no.
NM_001002027); B.tau, Bos taurus (bovine, residue 60 to 136; RefSeq accession no. NP_788822); and M.mus, Mus musculus (mouse, residue 60
to 136; RefSeq accession no. NM_007506). For comparison, the two transmembrane helices found in the structure of the Escherichia coli enzyme
are indicated below. The N-terminal part of the mitochondrial precursor sequence for the bovine and mouse subunit c is not shown. Amino acid
residues found to be important for drug sensitivity in M. tuberculosis (positions 63 and 66, numbering for M. tuberculosis) are indicated by boxes.
The glutamic acid residue E61 is an essential residue for proton translocation.
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